Reperfusion therapy in acute myocardial infarction: present status and controversy

Area of Science:

• Cardiology
• Emergency Medicine
• Pharmacology

Background:

• Coronary thrombolysis has transformed acute myocardial infarction (MI) treatment.
• Intravenous streptokinase and tissue-type plasminogen activator (t-PA) are established agents, with t-PA showing superior recanalization rates.
• Ongoing research explores novel thrombolytic agents.

Purpose of the Study:

• To review the efficacy and safety of current thrombolytic therapies for acute MI.
• To discuss the role of adjunctive treatments like aspirin and heparin.
• To evaluate the impact of percutaneous transluminal coronary angioplasty (PTCA) in conjunction with thrombolysis.

Main Methods:

• Review of large clinical trials (e.g., GISSI 2, ISIS 2) and studies comparing thrombolytic strategies (e.g., TIMI IIB).
• Analysis of complication rates, particularly intracranial hemorrhage.
• Assessment of outcomes for high-risk patients undergoing different treatment strategies.

Main Results:

• Both streptokinase and t-PA decrease mortality in acute MI.
• Aspirin has demonstrated mortality reduction benefits.
• PTCA combined with thrombolysis achieves frequent and persistent infarct artery recanalization with low mortality, especially in high-risk patients.
• The TIMI IIB study suggests comparable outcomes between conservative and invasive strategies, pending subgroup analysis.

Conclusions:

• Thrombolytic therapy, particularly with t-PA, is a cornerstone in acute MI management.
• Adjunctive aspirin and heparin play vital roles, though their optimal use is under investigation.
• Early mechanical revascularization via PTCA benefits high-risk patients.
• The role of thrombolysis in later stages of MI or acute ischemic syndromes requires further research.